DXD:TSX.V; TDSGF:OTCQB; 3D0:FSE

3D Signatures Inc.

3D Signatures Inc. is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of a patient's individual chromosomal arrangement − or signature. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease. Depending on the application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient.
DXD:TSX.V TDSGF:OTCQB 3D0:FSE

Expert Comments:

3D Signatures continues to advance its cutting-edge technology for prostate cancer liquid biopsies and Hodgkin's lymphoma tests.
read more >
Etienne Moshevich, Alphastox.com (3/2/17)
"I wanted to send out a quick update on 3D Signatures Inc. after two tremendous announcements last week that I believe the market totally missed, which is where we see a major buying opportunity. . . .3D has a disruptive platform technology and there’s no doubt in my mind that they have already caught the attention of major pharmaceutical companies. . .I see the prostate cancer and Hodgkin’s lymphoma programs as a major step forward in terms of validating the investment opportunity and driving the value creation process. DXD is at a strong support level with lots of good news expected over the next 6-12 months."

Shane Matte, BioTuesdays Publishing Co. (2/23/17)
"The validation program for 3D Signatures Inc.’s Hodgkin's lymphoma test (Telo-HL) is under way. Telo-HL is powered by the company's TeloView software platform. . .there is currently no biomarker available that can predict patient response to standard chemotherapy in HL patients, and thereby help guide treatment decisions on an individual basis. . .the ability to identify the appropriate treatment for an individual patient at the time of diagnosis should result in expedited use of alternative treatment options and cost savings to the payer."

Alphastox.com (1/22/17)
"We've been wildly successful with a couple of our biotech picks as 3D Signatures Inc. is up over 100% since our initial feature at $0.35/share! The company is just starting to get going and I feel we have a ton more room to grow in this deal."

Sean Zubick, Linkedin (1/14/17)
"The problem with prostate cancer diagnostics currently is the lack of methods effective in grouping low-risk patient with significant precision; the result is that anyone exhibiting signs of prostate cancer are subjected to painful and expensive treatment. . .3D Signatures Inc. is on the cusp of a solution that promises to revolutionize the diagnostics and treatment of diseases. By using it, doctors will be able to understand the severity of the illness in much better detail, and thus able to customize treatments for individual patients; this means more certainty in the course of treatment, while alleviating significant costs."

Ivan Lo, Equedia Letter (1/9/17)
"Data from a new study published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures Inc.'s technology platform, TeloView, may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined (hormonal) androgen deprivation therapy and radiation therapy. . .the study concluded that 3D telomere analysis of CTCs can reveal differences in therapeutic responses, providing a new opportunity for better treatment monitoring and management of patients with high-risk prostate cancer."

3D Signatures, a Canadian company developing a platform of "disruptive" personalized prognostic tests for patients with 13 different cancers and Alzheimer's disease, has attracted the attention of several stock watchers with its most recent announcements.
read more >
Jennifer Poland, BioTuesdays Publishing Co. (12/7/16)
"3D Signatures Inc. presented preliminary results of a collaborative initiative between the company and the Institut Universitaire de Cardiologie et de Pneumologie De Quebec, exploring the possibility of identifying a biological marker to distinguish between two deadly forms of lung cancer, multiple synchronous lung adenocarcinoma (AC) and metastatic lung AC, which is a significant unmet clinical need in the management of patients with multiple lung lesions. . .the preliminary results suggest that 3DS has a promising molecular imaging technology that has the potential to improve the management of AC patients who present with multiple lung lesions."

More Expert Comments

Experts Following This Company

Ivan Lo The Equedia Weekly Letter
Shane Matte – BioTuesdays Publishing Co.
Etienne Moshevich, Editor Alphastox.com
Jennifer Poland
James West, Publisher and Editor Midas Letter

The information provided above is from analysts, newsletters, the company and other contributors.

3D Signatures Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Disruptive Technology
 
Software as a Service (SaaS) Business Model
 
Attracting Industry Majors